Actions following adverse drug events – how do these influence uptake and utilisation of newer and/or similar medications

Barozzi, Nadia, Peeters, GMEE Geeske and Tett, Susan E. (2015) Actions following adverse drug events – how do these influence uptake and utilisation of newer and/or similar medications. BMC Health Services Research, 15 498: . doi:10.1186/s12913-015-1165-9


Author Barozzi, Nadia
Peeters, GMEE Geeske
Tett, Susan E.
Title Actions following adverse drug events – how do these influence uptake and utilisation of newer and/or similar medications
Journal name BMC Health Services Research   Check publisher's open access policy
ISSN 1472-6963
Publication date 2015-11-06
Year available 2015
Sub-type Article (original research)
DOI 10.1186/s12913-015-1165-9
Open Access Status DOI
Volume 15
Issue 498
Total pages 9
Place of publication London, United Kingdom
Publisher BioMed Central
Collection year 2016
Language eng
Formatted abstract
Background
Over the last decade, actions following some adverse drug events received major publicity. This study investigated changes in usage patterns of medications in Australia following two examples - rofecoxib market withdrawal (2004) and warnings about jaw necrosis following bisphosphonates (2007).

Methods
Dispensing data for COX-2 inhibitors (2000–2008) and anti-osteoporosis medications (2003–2012) were obtained from the Australian Pharmaceutical Benefits Scheme database. For bisphosphonates, data on Australian marketing expenditures were purchased from Cegedim R .

Results
For COX-2 inhibitors, celecoxib dispensing halved after rofecoxib withdrawal, but meloxicam dispensing increased by 60 %. When lumiracoxib was introduced (2006) there was uptake of prescribing at a faster rate than meloxicam in 2002, its first year of use. For bisphosphonates, alendronate had highest use at the time of the warnings (8.3 DDD/1000/day), dropping to 4.9 DDD/1000/day by 2012. In contrast, risedronate use rose 2007–2012 from 4.1 to 4.9 DDD/1000/day. There was 49 % increase in reported annual expenditure on detailing for risedronate from 2007 to 2008 (to AUD$7.3 million) and only 29 % increase for alendronate (to AUD$3.1 million).

Conclusions
The rapid uptake of prescribing of lumiracoxib and increased use of meloxicam flagged a concern, especially after rofecoxib withdrawal due to safety issues. Bisphosphonates are useful drugs, however the dramatic rise in expenditure on detailing, followed by a rise in utilisation of risedronate could suggest that adverse publicity triggered a marketing response. These examples highlight the importance of tracking utilisation of medication classes in real time, using different data as needed, to ensure that due caution is exercised (and quick intervention provided if needed) for medications in the same class.
Keyword Pharmacoepidemiology
Rofecoxib
Bisphosphonates
Adverse drug events
Post-marketing surveillance
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 1 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Fri, 13 Nov 2015, 12:40:06 EST by Ms Felicity Lindberg on behalf of School of Pharmacy